SPATA2-Mediated Binding of CYLD to HOIP Enables CYLD Recruitment to Signaling Complexes by Kupka, S et al.
ReportSPATA2-Mediated Binding of CYLD to HOIP Enables
CYLD Recruitment to Signaling ComplexesGraphical AbstractHighlightsd SPATA2 bridges the interaction between HOIP and CYLD
d CYLD recruitment to the TNFR1-signaling complex requires
SPATA2
d Loss of SPATA2 phenocopies absence of CYLD in TNFR1
signalingKupka et al., 2016, Cell Reports 16, 2271–2280
August 30, 2016 ª 2016 The Authors.
http://dx.doi.org/10.1016/j.celrep.2016.07.086Authors
Sebastian Kupka, Diego De Miguel,
Peter Draber, Luigi Martino,
Silvia Surinova, Katrin Rittinger,
Henning Walczak
Correspondence
h.walczak@ucl.ac.uk
In Brief
Kupka et al. show that the previously
demonstrated interaction of CYLD with
HOIP, which is required for recruitment of
CYLD into signaling complexes, is
indirect and mediated by SPATA2. Loss
of SPATA2 abrogates recruitment of
CYLD to signaling complexes and
consequently mimics CYLD deficiency
with regards to gene activation and
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Recruitment of the deubiquitinase CYLD to signaling
complexes is mediated by its interaction with HOIP,
the catalytically active component of the linear ubiq-
uitin chain assembly complex (LUBAC). Here, we
identify SPATA2 as a constitutive direct binding part-
ner of HOIP that bridges the interaction between
CYLD and HOIP. SPATA2 recruitment to TNFR1-
and NOD2-signaling complexes is dependent on
HOIP, and loss of SPATA2 abolishes CYLD recruit-
ment. Deficiency in SPATA2 exerts limited effects
on gene activation pathways but diminishes nec-
roptosis induced by tumor necrosis factor (TNF),
resembling loss of CYLD. In summary, we describe
SPATA2 as a previously unrecognized factor in
LUBAC-dependent signaling pathways that serves
as an adaptor between HOIP and CYLD, thereby
enabling recruitment of CYLD to signaling com-
plexes.INTRODUCTION
Over the past few years, the balancing roles of E3 ubiquitin li-
gases (E3s) and deubiquitinases (DUBs) in creating and de-
grading ubiquitin chains, respectively, have emerged as crucial
at regulating innate and adaptive immune responses (Fiil and
Gyrd-Hansen, 2014; Zinngrebe et al., 2014). There are eight
different kinds of ubiquitin chains that accomplish different
physiological outcomes (Yau and Rape, 2016). For example,
lysine 48 (K48)-linked chains target proteins for degradation
by the proteasome, whereas K63- and methionine 1 (M1)-
linked chains (the latter also referred to as linear ubiquitin
chains) are involved in the regulation of gene activation path-
ways and cell death (Chen and Sun, 2009; Iwai et al., 2014).
The differently linked types of ubiquitin chains are generated
by specific E3s and are degraded by specialized DUBs.
Hence, precise timing of the respective activities of these en-
zymes is paramount for fine regulation of the signaling output
generated by ubiquitin-involving signaling complexes (SCs)Cell R
This is an open access article und(Chen and Sun, 2009; Kupka et al., 2016; Zinngrebe et al.,
2014).
Tumor necrosis factor (TNF) binding to TNF receptor 1
(TNFR1) triggers formation of the TNFR1 signaling complex
(TNFR1-SC) (Walczak et al., 2012). Signals initiated from this
complex result in two very different outcomes: (1) induction
of gene activation via NF-kB and mitogen-activated protein
(MAP) kinases and (2) induction of cell death, which can either
be apoptotic or necroptotic. Linear ubiquitination, mediated by
the linear ubiquitin chain assembly complex (LUBAC), is crucial
in deciding the fate of cells upon TNF stimulation. In the absence
of LUBAC, the lack of linear ubiquitin chains in the TNFR1-SC re-
sults in defective recruitment of various components and com-
plex destabilization (Haas et al., 2009). This shifts the signaling
toward enhanced formation of a secondary SC, which induces
cell death (Peltzer et al., 2014), also referred to as complex II of
TNFR1 signaling (Newton and Manning, 2016). In addition, linear
and other ubiquitin linkages are removed by the DUB CYLD,
a process that is crucial to enable the formation of complex II,
as CYLD- deficient cells are resistant to TNF-induced cell death
(Draber et al., 2015; Moquin et al., 2013).
LUBAC targets within the TNFR1-SC include RIP1, NEMO,
TNFR1, and TRADD (Draber et al., 2015; Gerlach et al., 2011; To-
kunaga et al., 2011). Furthermore, LUBAC regulates signaling
through various other receptors, including CD40, NOD2, and
IL-1R (Damgaard et al., 2012; Emmerich et al., 2013; Gerlach
et al., 2011). LUBAC is composed of three subunits: SHARPIN,
HOIL-1, and the catalytic component HOIL-1 interacting protein
(HOIP) (Draber et al., 2015; Haas et al., 2009; Ikeda et al., 2011;
Kirisako et al., 2006; Tokunaga et al., 2011). Additionally, LUBAC
is associated with two DUBs: CYLD and OTULIN (Draber et al.,
2015; Elliott et al., 2014; Takiuchi et al., 2014). Interaction of
OTULIN and CYLD with HOIP is mutually exclusive (Draber
et al., 2015). Although CYLD is co-recruited into signaling com-
plexes via HOIP, OTULIN is not (Draber et al., 2015). The mech-
anistic explanation for this observation remains elusive, yet
together, these findings point toward specific and distinct func-
tions for OTULIN versus CYLD in regulating LUBAC.
Intriguingly, although the interaction of OTULIN with HOIP has
been shown to be direct andwas structurally characterized (Elliott
et al., 2014; Schaeffer et al., 2014), we were not able to detect
direct binding of CYLD to HOIP. This suggested the existence ofeports 16, 2271–2280, August 30, 2016 ª 2016 The Authors. 2271
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. SPATA2 Constitutively Interacts with LUBAC and Forms Part of the Native TNFR1-SC
(A) HOIP-deficient K562 cells were reconstituted with TAP-tagged wild-type (WT) HOIP or enzymatically inactive HOIP-C885S. HOIP-containing complexes were
purified and analyzed by mass spectrometry.
(B) TNFR1-SC was purified from A549 cells using TAP-TNF (500 ng/ml). Protein complexes were analyzed by mass spectrometry.
(C) Samples were prepared as in (A) and subjected to western blot analysis.
(D) U937 cells were stimulated with FLAG-TNF (500 ng/ml) for the indicated time. TNFR1-SC was purified using anti-FLAG beads and analyzed by western
blotting.(an) additional factor(s) mediating this interaction. The search for
such a factor resulted in the discovery of SPATA2 as a previously
unrecognized component of the TNFR1-SC andNOD2-SC,which
bridges the interaction between CYLD and HOIP by directly in-
teracting, via distinct domains, with both proteins.
RESULTS
SPATA2 Is a Component of the TNFR1-SC
To address whether there may be factors, in addition to CYLD,
that are constitutively associated with LUBAC and recruited to
the TNFR1-SC, we performed two different mass spectrometry
(MS) analyses using a modified tandem affinity purification
(TAP) approach. In the first one, we employed TAP-tagged
TNF (TAP-TNF) to identify components of the TNFR1-SC and
in the second one we expressed TAP-tagged HOIP (HOIP-
TAP). CYLD, and the other two LUBAC components, HOIL-1
and SHARPIN, served as positive controls in this analysis;
indeed, all three factors were identified in both proteomic
approaches as high-scoring interactors. SPATA2 was an
additional protein that was identified by both proteomic
approaches (Figures 1A and 1B; Tables S1 and S2). Thus,
SPATA2 was a candidate for a constitutive interaction partner
of LUBAC and for a previously unrecognized component of the
TNFR1-SC.2272 Cell Reports 16, 2271–2280, August 30, 2016We validated the constitutive interaction of SPATA2 with HOIP
by western blotting (Figure 1C). When examining whether
SPATA2 formed part of the native TNFR1-SC, we found that it
was recruited to this complex. In line with the constitutive inter-
action between SPATA2 and LUBAC, this occurred with kinetics
similar to those of HOIP and CYLD (Figure 1D). Hence, SPATA2
is a previously unrecognized component of the native TNFR1-SC
and a constitutive interaction partner of LUBAC.
SPATA2 Recruitment to the TNFR1- and NOD2-SC
Requires HOIP
We next tested whether SPATA2 was recruited to the TNFR1-SC
due to its constitutive interaction with HOIP, in a manner similar
to CYLD (Draber et al., 2015). This analysis revealed that SPATA2
was absent from the TNFR1-SC in HOIP-deficient A549 cells
(Figure 2A), indicating that recruitment of SPATA2 is dependent
on HOIP.
Despite the constitutive interaction between SPATA2 and
LUBAC, it was possible that linear ubiquitination could be
required for its recruitment to, or retention in, the TNFR1-SC.
This was, however, not the case, as SPATA2 recruitment was
unaltered in HOIP-deficient A549 cells reconstituted with an
inactive form of HOIP (HOIP-C885S) (Figure 2B). Hence,
SPATA2 recruitment to the TNFR1-SC requires LUBAC, but
not its catalytic activity.
Figure 2. SPATA2 Is Recruited to the
TNFR1-SC and NOD2-SC via HOIP
(A) WT or HOIP-deficient A549 cells were stimu-
lated with FLAG-TNF (500 ng/ml) for the indicated
times. TNFR1-SC was purified and analyzed by
western blotting.
(B) HOIP-deficient A549 cells were reconstituted
with either HOIP-WT or HOIP-CS, and TNFR1-SC
was purified as in (A).
(C) Wild-type (WT) or HOIP-deficient A549 cells
were stably transfected with NOD2-TAP, stimu-
lated with L18-MDP (200 ng/ml) for the indicated
times, and analyzed by western blotting.We previously showed that, in addition to the TNFR1-SC,
LUBAC also forms part of various other signaling complexes,
including the NOD2-SC (Damgaard et al., 2012; Draber et al.,
2015; Gerlach et al., 2011; Haas et al., 2009).We therefore tested
whether SPATA2 is also recruited to the NOD2-SC and, if so,
whether its recruitment requires HOIP. When stimulating A549
cells expressing FLAG-tagged NOD2 with L18-MDP and purify-
ing the resulting signaling complex, we found that SPATA2 was
readily recruited alongside HOIP and CYLD (Figure 2C). Impor-
tantly, SPATA2, like CYLD, was not recruited to the NOD2-SC
in cells devoid of HOIP (Figure 2C). Hence, SPATA2 forms part
of the NOD2-SC, and its recruitment is a result of its constitutive
interaction with LUBAC via HOIP.
SPATA2 Is Required for Recruitment of CYLD to the
TNFR1-SC
Comparison of protein levels in different knockout cells showed
that SPATA2 levels were drastically reduced in HeLa cells
deficient in CYLD but not in cells deficient in OTULIN or HOIP
(Figure 3A). This suggested that CYLD and SPATA2 might be
functionally connected and possibly interact with each other.
Previous data showed that the USP domain of CYLD is
associated with the PUB domain of HOIP (Takiuchi et al.,
2014). However, we could not detect a direct interaction be-
tween these domains by isothermal titration calorimetry (ITC)
(Figure 3B). Additionally, when we overexpressed CYLD in
HOIP-TAP-expressing cells, we found that overexpression only
marginally increased the amount of CYLD bound to HOIP as
compared to endogenous levels of CYLD (Figure 3C). This is in
stark contrast to the interaction of HOIP with OTULIN, which
was substantially increased by OTULIN overexpression (Fig-
ure 3C). This suggested that the interaction between HOIP
and CYLD is mediated by an additional factor, and we were
therefore prompted to test whether SPATA2 may function
as an adaptor. If this were the case, the interaction of HOIP
and CYLD should increase as a function of co-overexpres-
sion of SPATA2. Strikingly, the association of CYLD with HOIP
drastically increased when SPATA2 was also overexpressed
(Figure 3C). Accordingly, when we reduced SPATA2 levels by
RNAi and immunoprecipitated overexpressed FLAG-tagged
HOIP, the amount of CYLD associated with HOIP was drastically
decreased (Figure 3D).We next tested whether SPATA2 is required for recruitment of
CYLD to the TNFR1-SC. Analysis of the TNFR1-SC showed that,
compared to control cells, CYLD was virtually absent from the
TNFR1-SC that formed in cells in which SPATA2 expression
was suppressed by RNAi (Figure 3E). Together, this demon-
strates that SPATA2 serves as an adaptor between CYLD and
HOIP and that SPATA2 is required and sufficient for recruitment
of CYLD, via HOIP, to the TNFR1-SC.
The N Terminus of SPATA2 Interacts with the USP
Domain of CYLD, whereas Its C Terminus Binds to the
PUB Domain of HOIP
We and others previously showed that the (PUB)-domain of
HOIP is essential for recruitment of CYLD (Draber et al., 2015;
Elliott et al., 2014). To test whether SPATA2 interacts with
this domain, we reconstituted HOIP-deficient K562 cells with
FLAG-tagged truncated versions of HOIP and immunoprecipi-
tated the associated complex. This revealed that only constructs
encompassing the N-terminal PUB domain bound SPATA2 (Fig-
ure 4A). Additionally, we used a HOIP-PUB domain point mutant
(N102A), which abolishes the interaction of both OTULIN and
CYLD with HOIP (Draber et al., 2015; Elliott et al., 2014). Impor-
tantly, this mutant was also unable to restore SPATA2 recruit-
ment to the TNFR1-SC (Figure 4B). Together, these data indicate
that the PUB domain of HOIP is essential for the interaction
with SPATA2 and, consequently, for recruitment of CYLD to
the TNFR1-SC.
To characterize the interaction of SPATA2 with CYLD and
HOIP further, we expressed various deletion mutants of SPATA2
with a GFP tag. Immunoprecipitation of these truncated forms of
SPATA2 revealed that the interaction with CYLD is mediated by
the N terminus of SPATA2 as a fragment comprising amino acids
1–116 was sufficient to bind to CYLD (Figure 4C). In contrast,
only SPATA2 fragments comprising amino acids 167–417 bound
to HOIP (Figure 4C).
SPATA2 Contains a PIM that Mediates the Interaction
with the PUB Domain of HOIP
Because the N102A mutation in the PUB domain of HOIP abol-
ishes the interaction with OTULIN and SPATA2, we assumed
that, similar to OTULIN, SPATA2 might also contain a PUB-
domain interacting motif (PIM). To precisely map the interactingCell Reports 16, 2271–2280, August 30, 2016 2273
Figure 3. Binding of CYLD to HOIP and Its Recruitment to the TNFR1-SC Requires SPATA2
(A) HOIP, CYLD, or OTULIN were knocked out via clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 and levels of the indicated proteins
compared to HeLa WT by western blot analysis.
(B) ITC characterization of the interactions between (A) the HOIP-PUB domain (597 mM) and a peptide derived from the PIM motif (58 mM) of OTULIN and (B) the
HOIP-PUB domain (398 mM) and the CYLD-USP domain (40 mM). For each titration, the raw data and normalized integrated heats are reported.
(C) HEK293 cells were transfected with different combinations of CYLD, SPATA2, and OTULIN together with FLAG-HOIP. Protein complexes were subsequently
purified using anti-FLAG beads and analyzed by western blotting.
(D) SPATA2 expression was suppressed in FLAG-HOIP transfected HEK293 cells using siRNA. FLAG-HOIPwas subsequently immunoprecipitated and tested for
associated proteins by western blot analysis.
(E) A549 cells were transfected with control or SPATA2 siRNA. After 72 hr, cells were subjected to TNFR1-SC purification and analyzed by western blotting.peptide, we designed a peptide array, spotted on a nitrocellulose
membrane, composed of 20-mer peptides that overlap by one
amino acid and span amino acids 201–520 of SPATA2. Incuba-
tion with glutathione S-transferase (GST) or GST-tagged PUB
domain of HOIP identified that SPATA2 peptides corresponding
to amino acids 319–347 interacted specifically with HOIP’s PUB
domain (Figure 4D). The overlapping sequence between inter-
acting peptides suggests RGTYFSTQDDVDLYTDSEPR as the
PIM of SPATA2. Characterization of the interaction by ITC re-
vealed an affinity of 0.9 mM (Figure 4E). Additionally, sequence
alignment of this PIM from different species revealed a high
degree of evolutionary conservation (Figure 4F).
Together, these results show that SPATA2 contains two
distinct domains that are responsible for mediating the interac-
tion with CYLD and HOIP, respectively; while the N terminus of
SPATA2 binds to the USP domain of CYLD, the interaction
with HOIP is mediated via a highly conserved PIM located in2274 Cell Reports 16, 2271–2280, August 30, 2016the central portion of SPATA2, which is recognized by the PUB
domain of HOIP.
SPATA2 or CYLD Deficiency has Limited Effects on
TNF-Induced Gene Activatory Pathways
We next examined how SPATA2 knockdown affected TNF-
induced gene activation. To do so, we employed wild-type and
CYLD-deficient HeLa cells and depleted SPATA2 byRNAi before
stimulating these cells with TNF. This analysis revealed no
increase in the activation of NF-kB in SPATA2-depleted as
compared to control cells, whereas activation of c-Jun N-ter-
minal kinase (JNK) was only slightly increased (Figure 5A).
However, the same was true for CYLD-deficient cells, and,
importantly, no further increase was seen by concomitant
SPATA2 suppression (Figure 5A). Similarly, RNAi-mediated sup-
pression of SPATA2 in A549 cells did not increase TNF-induced
activation of NF-kB, but it did increase activation of JNK
Figure 4. A PIM in SPATA2 Interacts with the PUB Domain of HOIP, whereas Its N Terminus Binds to CYLD
(A) HOIP-deficient K562 cells reconstituted with vector control, FLAG-HOIP-WT, or different truncated versions of FLAG-HOIP were lysed and subjected to
immunoprecipitation (IP) of HOIP. Samples were subsequently analyzed by western blotting.
(B) HOIP-deficient A549 cells were reconstituted with HOIP-WT or HOIP-N102A. Cells were stimulated with FLAG-TNF and the resulting signaling complexes
subsequently purified using anti-FLAG IP. Samples were analyzed by western blotting.
(legend continued on next page)
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(Figure 5B). Because CYLD deficiency is generally assumed to
significantly affect TNF-induced NF-kB activation, we also stim-
ulated primary bone-marrow-derived macrophages (BMDMs)
with TNF and analyzed activation of JNK, extracellular signal-
regulated kinase (ERK), and NF-kB. In line with our observation
in cell lines, however, no difference in NF-kB activation could
be detected between CYLD-proficient and CYLD-deficient
BMDMs, whereas deficiency in CYLD resulted in a slight in-
crease in JNK and ERK activation in these cells (Figure 5C).
Thus, in all cell types we tested, SPATA2 or CYLD deficiency
had little if any effect on TNF-induced NF-kB activation but
slightly increased JNK activation.
SPATA2 Deficiency Diminishes TNF-Induced
Necroptosis
In addition to its proposed role in inhibiting gene activation
induced by various ligands, CYLD has been shown to enhance
TNF-mediated cell death. More specifically, necroptosis was
shown to require CYLD in L929 cells (Hitomi et al., 2008; Moquin
et al., 2013; O’Donnell et al., 2011). To test whether SPATA2 was
also required for necroptosis, we reduced SPATA2 or CYLD
expression in the murine cell line L929 using small interfering
RNA (siRNA) (Figures 5D and 5E) and stimulated these cells
with TNF/zVAD to induce necroptosis. This revealed that knock-
down of SPATA2 protected L929 cells from TNF/zVAD-induced
necroptosis to a similar extent as CYLD knockdown (Figure 5D).
Thus, like CYLD, SPATA2 serves as a factor that enables
TNF-induced cell death.
DISCUSSION
We previously showed that CYLD recruitment to the TNFR1-
SC requires HOIP (Draber et al., 2015). Here, we show that
SPATA2 is indispensable for CYLD recruitment to this complex
by bridging CYLD and HOIP. Like OTULIN, SPATA2 directly
binds to the PUB domain of HOIP, and their interactions are
mutually exclusive. Because SPATA2 also requires HOIP for
its recruitment to the NOD2-SC, we deem it likely that the
complex consisting of LUBAC, SPATA2, and CYLD is the
default complex recruited also to other receptor-associated
complexes known to involve CYLD and/or LUBAC (Douanne
et al., 2016; Tauriello et al., 2010). Given the growing relevance
of the equilibrium between ubiquitination and deubiquitination
in the regulation of signaling complexes (Harhaj and Dixit,
2012; Kupka et al., 2016; Yau and Rape, 2016) and the
involvement of CYLD in a wide number of signaling platforms
(Draber et al., 2015; Mathis et al., 2015; Reiley et al., 2006;
Tauriello et al., 2010; Zhang et al., 2011), the discovery of(C) Truncated forms of GFP-SPATA2 were expressed in HEK293 cells. Following a
blot analysis.
(D) Peptidearrays representingaminoacids 200–520ofSPATA2asa series of 20-me
OTULIN PIM peptide served as a positive control. One membrane was incubated w
HOIP (GST-PUB). Bound GST-containing protein was subsequently detected by H
(E) ITC characterization of the interaction between HOIP-PUB domain (500 m
(RGTYFSTQDDVDLYTDSEPR). The raw data and normalized integrated heats ar
(F) Sequence alignment of the SPATA2 PIM region in different species. Underlin
mydas; Ap, Anas platyrhynchos; Gg, Gallus gallus; Mm, Mus musculus; Oa, Ovis
2276 Cell Reports 16, 2271–2280, August 30, 2016SPATA2 as a previously unrecognized adaptor between
CYLD and HOIP by us and others (Wagner et al., 2016)
provides additional insight on the mechanisms by which
this DUB controls the outcome of these diverse signaling
processes.
TNF-stimulated signaling induces gene activation pathways
and, under certain circumstances, programmed cell death
(Sedger and McDermott, 2014; Wertz, 2014). Here, we show
that in absence of SPATA2, CYLD is not recruited to the
TNFR1-SC. Therefore, absence of SPATA2 should affect TNF-
induced signaling in a manner similar to the absence of CYLD.
Previous studies reported the importance of CYLD for induction
of necroptosis (Hitomi et al., 2008; Moquin et al., 2013; O’Don-
nell et al., 2011). In line, siRNA-mediated knockdown of SPATA2
or CYLD protected cells from TNF-induced necroptosis to a
similar extent, Likewise, suppression of SPATA2 correlated
with that of CYLD regarding gene activation pathways, exerting
minor effects on TNF-induced NF-kB activation but showing a
slight effect on JNK activation in the different cell types tested.
This is in apparent contrast to the accepted role of CYLD as a
negative regulator of NF-kB activation and results presented
on the role of SPATA2 in gene activation while our study was
under review (Wagner et al., 2016). It should be noted, however,
that most studies investigating the role of CYLD in NF-kB activa-
tion were performed using overexpression models and/or lucif-
erase reporter assays, mostly in HEK293 cells (Brummelkamp
et al., 2003; Kovalenko et al., 2003; Trompouki et al., 2003).
The physiological relevance of these results is at least arguable,
since they are based on artificial and isolated reporter elements.
Indeed, luciferase reporter assays have already been described
to be unreliable under certain circumstances, specifically in
HEK293 cells (Ling et al., 2012). In fact, several studies previ-
ously reported only minimal effects of CYLD deficiency on
TNF-induced gene activation in general and a slight increase
of JNK activation (Moquin et al., 2013; Reiley et al., 2006;
Zhang et al., 2006). Together, it appears that the role of CYLD
with respect to gene activation is certainly more cell-type
and pathway dependent than currently thought. Our results on
SPATA2 and CYLD, in connection with the previous literature
on CYLD, provide the rationale for a thorough reassessment
of the effects of deficiency in CYLD, and now also of SPATA2,
on gene activation induced by different stimuli and in different
cell types.
Initially, SPATA2 was described as a protein that might
be involved in spermatogenesis, as it is highly expressed in testis
and strongly upregulated during spermatogenesis (Onisto et al.,
2001). Interestingly, CYLD-deficient mice, despite having no
overt phenotype, have been reported to show defects innti-GFP IP, SPATA association with HOIP and CYLDwas evaluated by western
r overlappingpeptides, shiftedbyone, blottedonnitrocellulosemembranes.The
ith recombinant GST-only (GST) the other one with GST-tagged PUB-domain of
RP immunofluorescence, and the signal of both membranes was overlaid.
M) and a peptide (50 mM) derived from the C-terminal region of SPATA2
e reported.
ed sequence indicates the peptide used in (E). Dr, Danio rerio; Cm, Chelonia
aries; Ec, Equus caballus; Pt, Pan troglodytes; Hs, Homo sapiens.
Figure 5. SPATA2 Deficiency Reduces TNF-Induced Necroptosis but Has Minor Effects on TNF-Mediated Gene Activation
(A) SPATA2 levels were reduced by siRNA in HeLaWT and HeLa CYLD-KO cells. Cells were then stimulated with TNF for the indicated time, lysed, and subjected
to western blot analysis.
(B) Knockdown of SPATA2 was performed in A549 by siRNA. Cells were then stimulated with TNF for the indicated time, lysed, and subjected to western blot
analysis.
(C) Bone-marrow-derived macrophages were isolated from CYLD-deficient mice or wild-type littermates. Cells were then stimulated with TNF and analyzed by
western blotting.
(D) SPATA2 or CYLD expression in L929 was silenced by siRNA. Cells were stimulated with 20 ng/ml TNF and the indicated inhibitors. After 16 hr, cells were
collected, stained with propidium iodide, and measured by fluorescence-activated cell sorting (FACS). Data are presented as mean ± SEM (n = 3); **p < 0.01,
statistics were performed using a two-tailed, unpaired Student’s t test.
(E) Representative western blot analysis of the knockdown efficiency in L929 cells used in the experiment shown in (D).spermatogenesis (Wright et al., 2007). In light of our result that
CYLD-deficient cells have drastically reduced SPATA2 levels, it
is possible that these defects are due to SPATA2 deficiency. It
will be interesting to investigate the connection between CYLD
and SPATA2 with regards to defects in spermatogenesis, i.e.,
whether in this context the function of SPATA2 is CYLD
dependent.The observation that SPATA2 plays an important role in CYLD
function could be of clinical relevance, as patients withmutations
in CYLD develop cylindromatosis (Biggs et al., 1995). A first anal-
ysis of the publicly available databases for autoimmune patients
did not reveal any overt polymorphisms in the SPATA2 gene.
However, it is possible that SPATA2mutations could be involved
in patients suffering from cylindromatosis or related diseasesCell Reports 16, 2271–2280, August 30, 2016 2277
who do not have mutations in CYLD and for whom a molecular
explanation is consequently still missing (Dubois et al., 2015;
Saggar et al., 2008).
EXPERIMENTAL PROCEDURES
Plasmids and Cloning
SPATA2 was cloned from cDNA by conventional PCR using 50-atggggaagcc
cagttca-30 as the forward and 50-ctatctgtacacgagatgggagag-30 as the reverse
target sequence. HOIP and CYLD expression constructs were described
previously (Draber et al., 2015).
SDS-PAGE, Western Blot, and Antibodies
Proteins were separated on 4%–15% Mini-PROTEAN TGX Precast Gels with
TGX running buffer. Proteins were transferred onto 0.2 mMnitrocellulose mem-
brane (Bio-Rad, Trans-Blot TurboMini Nitrocellulose Transfer Packs). Proteins
were detected via western blot using the following antibodies: SPATA2 (Ab-
cam, ab56565), SPATA2 (Bethyl Laboratories, A302-494A), HOIP (Aviva Sys-
tem Biology, ARP43241_P050), SHARPIN (Proteintech, 14626-I-AP), HOIL-1
(Haas et al., 2009), CYLD (Santa Cruz Biotechnology, sc-74435), OTULIN (Ab-
cam, ab151117), RIP1 (BD, 610459), TNFR1 (Santa Cruz, 8436), M1-Ub (Merck
Millipore, MABS199), IkBa (Cell Signaling Technology, 9242), pIkBa (Cell
Signaling, 9246S), pP65 (Cell Signaling, 7F1), pErk (Santa Cruz, SC-7383),
pP38 (Cell Signaling, D3F9), pJNK (Cell Signaling, 98F2), Actin (Sigma-Aldrich,
A1978), GAPDH (Abcam, ab8245), FLAG (Sigma-Aldrich, M2), and GST (Cell
Signaling, 2622).
Production of Recombinant TNF
The coding sequences of TAP-TNF, consisting of a His-tag followed by 3x
FLAG tag, a PreScission cleavage site, and a 2x Strep-tag II, and the extracel-
lular portion of TNF (aa 78–233) or His-TNF (aa 78–233) were inserted in pQE30
vector. Protein was expressed in BL21 (DE3) cells with 1 mM isopropyl b-D-1-
thiogalactopyranoside (IPTG) overnight and purified by affinity chroma-
tography on His GraviTrap TALON columns (GE Healthcare), eluted with
500 mM imidazole and dialyzed against storage buffer (50 mM Tris [pH 7.4],
100 mMNaCl, 0.02% Tween, 2 mMDTT, and 0.5 M arginine). Protein concen-
tration was determined with a Nanodrop 2000 (Thermo Scientific) and samples
were stored at 20C.
Transient Transfection
Cells were seeded the day before and allowed to reach 70% confluency on
the day of transfection. For a six-well plate, 1 mg DNA was used per well. First,
DNA was diluted in 100 ml Opti-MEM medium, and TurboFect transfection re-
agent (Thermo Scientific) or Lipofectamine 2000 (Thermo Fisher) was added in
a 1:3 DNA/transfection reagent ratio. After a 30 min of incubation, the mixture
was added dropwise to the cells. Cells were allowed to grow for another day
before use for experiments.
siRNA-Mediated Knockdown
Transient knockdown was performed by reverse transfection of cells with
siRNA using Lipofectamine 2000 (Invitrogen) following the manufacturer’s rec-
ommendations. In summary, Lipofectamine 2000 was added to medium free
of FCS and antibiotics and incubated for 20 min at room temperature. Next,
siRNA was added and left at room temperature for 30 min. The reaction mix
was then added dropwise to the cells, and the final volume was adjusted
with antibiotic free medium. The ratio of Lipofectamine/siRNA was 3 ml/mg
siRNA in all cases. All experiments were carried out at least 48 hr after the
reverse transfection.
Immunoprecipitation of Protein Complexes
For immunoprecipitation of ectopically expressed tagged proteins, cells were
lysed in immunoprecipitation (IP)-lysis buffer and lysate was cleared by centri-
fugation. FLAG-tagged proteins were immunoprecipitated using anti-FLAG
(M2) beads (Sigma-Aldrich).Where other antibodies have been used, 1 mg anti-
body was bound to Protein A/G beads (Santa Cruz Biotechnology) prior to the
addition to the lysate. Immunoprecipitations were carried out at 4C with2278 Cell Reports 16, 2271–2280, August 30, 2016gentle rotation for 4–16 hr. Beads were then washed three times with lysis
buffer and reduced using LDS sample buffer.
TNFR1-SC Purification
FLAG-tagged TNF (1 mg/ml) in medium (37C) was added to the cells for the
indicated time. Cells were left in the incubator during the course of stimulation.
Subsequently, stimulation medium was aspirated and cells were washed with
cold PBS. Cells were lysed in IP-lysis buffer and cellular debris was cleared by
centrifugation at 13,000 rpm for 20 min. 1/100 of the amount of FLAG-TNF
used for the stimulation was added to lysates from non-stimulated cells as a
negative control. 10 mg M2 beads (Sigma-Aldrich) were then added to the
lysate and incubated overnight at 4C. The next day, samples were washed
three times with IP buffer and then reduced in sample buffer.
Mass Spectrometric Analysis of Immunoprecipitated Complexes
Protein complexes were processed and analyzed as in Draber et al. (2015). In
brief, protein mixtures were denatured, reduced, alkylated, and digested with
Lys-C and Trypsin. Desalted samples were analyzed by nLC-MS/MS on a Q
Exactive Orbitrap coupled to an Easy-nLC 1000 (Thermo Scientific).
Isolation of Bone-Marrow-Derived Macrophages
For preparation of BMDMs, 8-week-old mice were sacrificed. Hindlimbs were
removed, and bones were separated frommuscle tissue. Femur and tibia were
opened on each site, and bone marrow was flushed out using a 25G needle
and syringe. Cells were then resuspended in RPMI medium containing 10%
fetal calf serum (FCS), 1% penicillin/streptomycin (Invitrogen), and 10%
conditioned medium from L929 cells and passed through a cell strainer. Sub-
sequently, cells were plated in a 12-well plate. The conditioned medium was
replaced every 2 days, and cells were incubated for 7 days before the
experiment.
Cell Death Analysis
Cells were treated with 200 ng/ml TNF or in combination with 20 mM zVAD-fmk
(Abcam) and/or 10 mMNec-1 s (Biovision) for 24 hr. Supernatant was collected
and remaining live cells were trypsinized. Supernatant and detached cells
were combined and centrifuged at 2,500 rpm for 10 min. The pellet was then
resuspended in PBS containing 5 mg/ml propidium iodide (Sigma). Cells
were analyzed by FACS (BD Accuri C6 or Fortessa). Data are presented as
mean ± SEM (n = 3), and statistics were performed using t tests.
Peptide Arrays
Peptide arrays covering residues 200–520 of SPATA2 as a series of 20-mer
overlapping peptides were synthesized by the Peptide Chemistry Science
Technology Platform of the Francis Crick Institute. Arrays were activated
with 70% ethanol for 15min and blocked with 5%milk powder in PBS contain-
ing 0.05% Tween-20 (PBST). After blocking, the membranes were washed
three timeswith PBST. Recombinant GST or GST-PUB-HOIP in PBST contain-
ing 2.5% BSA was added to the respective membrane. The blots were incu-
bated for 1 hr at room temperature with gentle agitation, washed three times
with PBST, and subsequently incubated with anti-GST primary antibody and
detected with horseradish peroxidase (HRP)-coupled anti-rabbit antibody.
Isothermal Titration Calorimetry
ITC experiments were performed at 293 K using an ITC-200 microcalorimeter
(Malvern Instruments). The protein and peptide solutions were prepared in
25 mMHEPES (pH 7.5), 150 mMNaCl, and 0.5 mM TCEP. Titrations were per-
formed by titrating 20 times 2 ml HOIP-PUB domain (597 mM) into the OTULIN
peptide (AEHEEDMYRA) at 58 mM, 398 mMHOIP-PUB domain into the CYLD-
USP domain at 40 mM, and 500 mM HOIP-PUB domain into the SPATA2 pep-
tide (RGTYFSTQDDVDLYTDSEPR) at 50 mM. Integrated heats corrected for
heats of dilution were fitted using a 1:1 binding model in the MicroCal-Origin
7.0 software package.
Statistical Procedures
Where indicated, data from at least three biological replicates are presented
as mean ± SEM. Statistical significance was calculated by performing a
two-tailed, unpaired Student’s t test, with ** indicating p% 0.01.
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